LYRA THERAPEUTICS INC

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 11 2024 16:01:58 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

15 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

27 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

14 8 2024 16:01:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

21 5 2024 09:14:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

06 5 2024 07:59:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

30 4 2024 16:04:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

26 4 2024 16:51:11 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

21 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 3 2024 16:01:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 11 2023 16:01:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics to Participate in Upcoming Investor Conferences

07 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer

16 10 2023 07:00:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

12 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics to Participate in Upcoming Investor Conferences

06 9 2023 15:00:28 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

29 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

08 8 2023 16:01:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

13 7 2023 07:30:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 6 2023 16:01:00 提供 Nasdaq GlobeNewswire

Lyra Therapeutics to Present at Jefferies Healthcare Conference

02 6 2023 07:30:00 提供 Nasdaq GlobeNewswire